Swissmedic issues a patient-centric recall for specific batches of Algifor Junior Suspension 200 ml and Algifor Dolo Junior Suspension 200 ml following quality concerns.
Effective November 28, 2025, Swissmedic has announced a batch recall of the two mentioned pharmaceutical products, emphasizing retrieval at the patient level. Regulatory and healthcare stakeholders are advised to act promptly to ensure compliance and patient safety.
What changed?
Swissmedic has mandated the recall of specific batches of Algifor Junior Suspension and Algifor Dolo Junior Suspension. The corrective action focuses on reaching patients who may have already received affected products. The decision follows quality concerns, signaling potential risks that warrant heightened safety measures.
Who is affected?
This recall impacts patients, caregivers, clinicians, and pharmacists who may have dispensed or used the affected products. The recall process extends beyond healthcare providers and distributors to ensure corrective action directly at the patient level.
Investigation details
Why are these batches recalled?
Swissmedic identified possible quality defects in the specified batches of Algifor Junior Suspension (200 ml) and Algifor Dolo Junior Suspension (200 ml). While the exact nature of the issue remains protected for regulatory discussions, the patient-level recall underscores its significance.
Recalled batch information
The recall involves limited batch numbers. Healthcare providers are advised to cross-verify patient inventory and distribution records for compliance with Swissmedic’s guidance. Detailed batch numbers and instructions can be found on Swissmedic’s official statement here.
Next steps
Healthcare institutions and stakeholders must:
- Stop distribution and use of affected batches.
- Notify patients who possess recalled products.
- Follow Swissmedic’s prescribed handling, collection, and disposal protocols.
- Communicate closely with pharmacists, clinicians, and local health authorities to reach all impacted individuals.
Frequently Asked Questions (FAQ)
Q1. What products are involved?
A1. The recall targets Algifor Junior Suspension 200 ml and Algifor Dolo Junior Suspension 200 ml, specified by batch numbers under Swissmedic guidance.
Q2. Are these products still available?
A2. Affected batches should not be available. Distribution stakeholders must remove them promptly.
Q3. How can patients check their batch?
A3. Patients should consult packaging labels for batch identifiers and contact healthcare providers if unsure.
Conclusion
The recall by Swissmedic prioritizes patient safety, urging healthcare and regulatory teams to align outreach and compliance efforts. Reporting and disposal channels must remain streamlined to meet recall objectives effectively. Prompt adherence to recall measures is vital for safety.
Disclaimer
This post provides informational content derived from official Swissmedic communications. It does not constitute legal advice or guidance. Always consult regulatory documents for reference.
Swissmedic Source
For full information about the Swissmedic announcement, see the link below.
https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/qualitaetsmaengel-und-chargenrueckrufe/batch-recalls/chargenrueckruf-algifor-junior-suspension-algifor-dolo-junior-suspension.html